Supreme Court Strikes Down Chevron. What’s Next?

A Friday Supreme Court ruling could create uncertainty for the medtech industry by giving judges more latitude to overrule executive-branch decisions. While some pro-business groups applauded the decision, others saw risks as well as benefits.

US Supreme court building with 1st statue on left

Federal agencies like the US Food and Drug Administration took a major blow to their powers on Friday with a US Supreme Court decision striking down what’s known as the Chevron doctrine, a 40-year-old principle that required courts to defer to regulators when statutory language is ambiguous.

The 6-3 ruling in Loper Bright Enterprises et al. v. Raimondo et al., was divided along ideological lines. The court found that Chevron had gone too far in requiring courts to back administrative interpretations

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

More from Policy & Regulation